GLP-1 체중 감량 약물: 오젬픽, 위고비 총정리
빠른 답변: GLP-1 수용체 작용제(GLP-1 Receptor Agonists)인 세마글루타이드(Semaglutide)는 평균 15-17%의 체중 감량을 달성합니다. 오젬픽(Ozempic, 주사용 세마글루타이드, 최대 1mg/주)은 원래 2형 당뇨병용이며, 위고비(Wegovy, 주사용 세마글루타이드, 최대 2.4mg/주)는 체중 감량 전용으로 승인되었습니다. 작용 기전: GLP-1 호르몬을 모방하여 위 배출 지연, 포만감 증가, 식욕 억제, 인슐린 감수성 개선. STEP 임상시험에서 위고비 2.4mg/주는 평균 약 15% 체중 감소를 보였습니다. 흔한 부작용: 오심(약 40%, 보통 점차 완화), 구토, 설사, 변비. 드물지만 심각한 위험: 췌장염, 담낭 질환. 중요 참고: 생활 습관 변화 없이 중단하면 약 2/3의 감량 효과가 1년 이내에 반등할 수 있습니다.
Disclaimer: 이 내용은 정보 제공 목적이며 의료 조언이 아닙니다. 전체 면책조항.
How Do GLP-1 Medications Work for Weight Loss?
GLP-1 (glucagon-like peptide-1) receptor agonists represent the most significant advancement in obesity treatment in decades. These medications mimic a natural gut hormone that regulates appetite and blood sugar:
- Appetite suppression: GLP-1 acts on brain receptors in the hypothalamus to reduce hunger and increase satiety, leading to naturally reduced food intake of 20-30%
- Slowed gastric emptying: Food stays in the stomach longer, prolonging feelings of fullness after meals
- Improved insulin sensitivity: Originally developed for type 2 diabetes, these medications reduce insulin resistance and blood sugar spikes
- Reduced food reward: Emerging neuroimaging research suggests GLP-1 agonists decrease the brain's reward response to high-calorie foods
The currently available medications include:
- Semaglutide (Wegovy): FDA-approved for weight management at 2.4mg weekly injection. Also sold as Ozempic (1-2mg) for diabetes.
- Tirzepatide (Mounjaro/Zepbound): A dual GIP/GLP-1 agonist showing even greater weight loss in trials (up to 22.5% body weight).
- Liraglutide (Saxenda): An older GLP-1 agonist with more modest results (5-8% weight loss).
What Results Can You Expect from GLP-1 Medications?
Clinical trial data provides a clear picture of expected outcomes:
- STEP 1 trial (NEJM, 2021): Semaglutide 2.4mg produced average weight loss of 14.9% (vs. 2.4% placebo) over 68 weeks in adults with obesity. One-third of participants lost 20%+ body weight.
- SURMOUNT-1 trial (NEJM, 2022): Tirzepatide at highest dose produced average 22.5% weight loss over 72 weeks — approaching bariatric surgery results.
- Cardiovascular benefits: The SELECT trial (2023) showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established heart disease.
Important caveats:
- Weight regain: The STEP 1 extension study found participants regained two-thirds of lost weight within 1 year of stopping the medication
- Muscle loss: Approximately 25-40% of weight lost is lean mass (muscle), which is a concern for long-term metabolic health. Resistance training and adequate protein (1.6g+/kg) are essential adjuncts.
If you are prescribed a GLP-1 medication, use WAYJET's Prescription Analyzer to verify dosing guidelines and check for interactions with your other medications.
What Are the Side Effects and Risks?
GLP-1 medications have a generally well-established safety profile, but side effects are common, especially during dose escalation:
- Gastrointestinal (most common): Nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). Usually mild-to-moderate and improve over 4-8 weeks.
- Gallbladder issues: Rapid weight loss increases gallstone risk. The STEP trials reported cholelithiasis in 2-3% of semaglutide users vs. 1% placebo.
- Pancreatitis: Rare (0.1-0.3%) but serious. Seek immediate care for severe abdominal pain.
- Thyroid C-cell tumors: Observed in rodent studies at high doses. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.
Who should NOT take GLP-1 medications:
- Personal/family history of medullary thyroid cancer or MEN2
- History of pancreatitis
- Pregnant or planning to become pregnant (stop at least 2 months before conception for semaglutide)
- History of severe gastrointestinal disease
Cost remains a significant barrier: without insurance, Wegovy costs approximately $1,300-1,600 per month. Coverage varies significantly by insurer and employer plan.
자주 묻는 질문
What is the difference between Ozempic and Wegovy?
Both contain semaglutide but differ in approved use and dosing. Ozempic is FDA-approved for type 2 diabetes (max dose 2mg weekly), while Wegovy is approved for weight management (dose 2.4mg weekly). Wegovy was specifically studied in obesity trials. Using Ozempic off-label for weight loss is common but may not be covered by insurance for that purpose.
Do you have to take GLP-1 medications forever?
Current evidence suggests most people regain weight after discontinuation. The STEP 4 trial showed continued weight loss with ongoing treatment vs. significant regain when switched to placebo. Long-term use appears necessary for sustained results, similar to other chronic disease medications. Ongoing research is exploring whether lifestyle modifications during treatment can improve post-cessation outcomes.
Can GLP-1 medications cause hair loss?
Hair loss (telogen effluvium) has been reported in clinical trials, affecting about 3-5% of semaglutide users. This is likely triggered by rapid weight loss rather than the medication itself — any significant weight loss can cause temporary shedding. Hair typically regrows once weight stabilizes. Adequate protein and micronutrient intake may help minimize this side effect.
관련 글
--- WAYJET 분석 ---